| Treatment | N | Median PFS (months) | |
| EGFR-TKI |
| ||
| NEJ2002 [7] [8] | Gefitinib vs. chemo | 230 | 10.8 vs 5.4 |
| WJTOG3405 [9] [10] | 177 | 9.7 vs. 6.3 | |
| LUX-Lung 3 [11] | Afatinib vs. chemo | 345 | 11.1 vs. 6.9 |
| LUX-Lung 6 [12] | 364 | 11.0 vs. 5.6 | |
| OPTIMAL [13] | Erlotinib vs. chemo | 154 | 13.1 vs. 4.6 |
| EURTAC [14] | 173 | 9.7 vs. 5.2 | |
| ENSURE [15] | 217 | 11.5 vs. 5.5 | |
| ALK-TKI |
| ||
| ALUR | Alectinib vs. chemo | 107 | 9.6 vs 1.4 |
| ASCEND-5 | Ceritinib vs. chemo | 231 | 5.4 vs 1.6 |
| ASCEND-4 | 376 | 16.6 vs 8.1 | |
| NCT00932893 | Crizotinib vs. chemo | 347 | 7.7 vs 3.0 |
| NCT03052608 | Lorlatinib vs. Crizotinib | 296 | 79% vs 39% (1 year event free survival) |
| Immunotherapy |
| ||
| KEYNOTE-189 | Pembrolizumab + Chemo vs. Chemo | 616 | 8.8 vs 4.9 (Median PFS) |
| IMPower110 | Atezolizumab vs Chemo | 205 | 20.2 vs 13.1 |
| ÌMPower150 | ABCP vs BCP | 692 | 19.2 vs 14.7 |
| CheckMate227 | Nivolumab + Ipilimumab vs Chemotherapy | 1739 | 17.1 vs 14.9 (PD-L1 ≥ 1%) 17.2 vs 12.2 (PD-L1 < 1%) |